Latest news with #MAVERIC
Sydney Morning Herald
a day ago
- Science
- Sydney Morning Herald
Nvidia supercomputer marks ‘new era' for Australian AI
Nvidia, the world's most valuable company, is teaming with Monash University and Dell to build an Australia-first supercomputer that promises to elevate the country into the AI big leagues. The supercomputer, dubbed MAVERIC and built in collaboration with CDC Data Centres, will be purpose-built for large-scale AI and data-intensive workloads and feature technology never before deployed in the country. MAVERIC will be housed at CDC's facility in the Melbourne suburb of Brooklyn, with construction to begin later this year. The system is expected to go live in early 2026, and was the subject of a meeting between Australia's ambassador to the US Kevin Rudd, Assistant Minister for Science Andrew Charlton and Nvidia executives on Wednesday morning. 'Without this kind of AI super-computer power, Australian researchers are trying to compete on the world stage with one arm tied behind their back,' Monash University vice-chancellor Sharon Pickering said in an interview. 'We are making a $60 million investment here so that Australia can be world leaders, and not just be willing to take second place. We have to be willing to be the best in the world and for our world-leading researchers; my job is to get them the best infrastructure in the world to support them.' MAVERIC will initially focus on advancing medical research, Pickering said, including developing new pharmaceutical products and personalising treatments for patients suffering from acute medical conditions. It will also focus on environmental issues including a study of the Antarctic and research into the impact of heat on populations. It will be available to university researchers and academics, students and research partners. The supercomputer will be built using Dell racks and servers and feature Nvidia's GB200 NVL72 platform. Amid debate about Australia's role in the global AI arms race, Dell Australia managing director Angela Fox said that MAVERIC represented a 'leapfrogging' opportunity for the nation in its AI capabilities. 'It allows researchers to use increasingly sophisticated AI models to tackle some of Australia and the world's most pressing issues and will deliver lasting value for the nation,' she said. 'It's a massive win for the research community and for Australia as a whole.'
The Age
a day ago
- Science
- The Age
Nvidia supercomputer marks ‘new era' for Australian AI
Nvidia, the world's most valuable company, is teaming with Monash University and Dell to build an Australia-first supercomputer that promises to elevate the country into the AI big leagues. The supercomputer, dubbed MAVERIC and built in collaboration with CDC Data Centres, will be purpose-built for large-scale AI and data-intensive workloads and feature technology never before deployed in the country. MAVERIC will be housed at CDC's facility in the Melbourne suburb of Brooklyn, with construction to begin later this year. The system is expected to go live in early 2026, and was the subject of a meeting between Australia's ambassador to the US Kevin Rudd, Assistant Minister for Science Andrew Charlton and Nvidia executives on Wednesday morning. 'Without this kind of AI super-computer power, Australian researchers are trying to compete on the world stage with one arm tied behind their back,' Monash University vice-chancellor Sharon Pickering said in an interview. 'We are making a $60 million investment here so that Australia can be world leaders, and not just be willing to take second place. We have to be willing to be the best in the world and for our world-leading researchers; my job is to get them the best infrastructure in the world to support them.' MAVERIC will initially focus on advancing medical research, Pickering said, including developing new pharmaceutical products and personalising treatments for patients suffering from acute medical conditions. It will also focus on environmental issues including a study of the Antarctic and research into the impact of heat on populations. It will be available to university researchers and academics, students and research partners. The supercomputer will be built using Dell racks and servers and feature Nvidia's GB200 NVL72 platform. Amid debate about Australia's role in the global AI arms race, Dell Australia managing director Angela Fox said that MAVERIC represented a 'leapfrogging' opportunity for the nation in its AI capabilities. 'It allows researchers to use increasingly sophisticated AI models to tackle some of Australia and the world's most pressing issues and will deliver lasting value for the nation,' she said. 'It's a massive win for the research community and for Australia as a whole.'
Yahoo
22-07-2025
- Business
- Yahoo
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients. Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardiac death. There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis. Topline results are expected within the next two weeks. Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced database lock for ARCHER, the Company's Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating its lead asset, CardiolRx™, on myocardial recovery in patients with acute myocarditis. "Database lock marks another important milestone in the ARCHER program, enabling statistical analysis, unblinding, and the reporting of topline results, which are now expected within the next two weeks," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "As we advance our lead program—the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis—we believe results from ARCHER will further guide our broader development strategy in forms of heart disease where fibrosis plays a key role." Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development, added, "Acute myocarditis remains a serious and underserved cardiovascular condition with no approved pharmacological therapy, underscoring the significance of ARCHER. On behalf of the ARCHER Steering Committee and Cardiol Therapeutics, I would like to thank our clinical investigators and the patients and their families for their essential contributions. We look forward to receiving the results of the statistical analysis, which we believe will provide important insights into the effects of CardiolRx™ on MRI-based measures of cardiac fibrosis and function in patients with myocarditis." ARCHER is a Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx™ on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal ESC Heart Failure. The study enrolled over 100 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel. The two primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac magnetic resonance imaging parameters: global longitudinal strain and extra-cellular volume, which assess myocardial function and tissue characteristics associated with fibrosis and inflammation. Both parameters are recognized prognostic markers in patients with acute myocarditis. Acute Myocarditis Acute myocarditis is an inflammatory condition of the heart muscle (myocardium) characterized by chest pain, shortness of breath at rest or during activity, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness or the feeling one might faint. The disease is an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Viral infection is the most common cause of myocarditis; however, it can also result from bacterial infection, commonly used drugs, and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. There are no FDA-approved drug therapies for acute myocarditis. Patients hospitalized with the condition experience an average seven-day length of stay and a 4 - 6% risk of in-hospital mortality, with average hospital charge per stay estimated at $110,000 in the United States. About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually. For more information about Cardiol Therapeutics, please visit Cautionary statement regarding forward-looking information: This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure, the Company's preparation for statistical analysis, unblinding, and reporting of top-line results from its Phase II ARCHER trial of CardiolRx™ in acute myocarditis, and the Company's belief that results from the ARCHER trial will provide insights to help guide its broader development strategy in forms of heart disease where fibrosis plays a key role, and into the effects of CardiolRx™ on MRI-based measures of cardiac fibrosis and function in patients with myocarditis. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at and EDGAR at as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. For further information, please contact:Trevor Burns, Investor Relations + To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Sea Teknik Robotics launches MAVERIC to transform maritime maintenance
Sea Teknik Robotics has entered the maritime technology sector with the launch of its flagship product, the M.A.V.E.R.I.C (Modular, Autonomous, Versatile, Engineered for Robotic Inspection & Cleaning). Founded by Suhaimee Nosman and Lina Soho in Singapore, the company aims to advance marine maintenance and inspection processes. The MAVERIC addresses the growing demand for underwater hull cleaning, a service often constrained by existing capacity, according to the company. Unlike traditional remotely operated vehicles (ROVs) that serve a single purpose, the MAVERIC is designed as an advanced platform capable of performing multiple operations. It features a proprietary swappable skid system and a modular interface, enabling quick reconfiguration for tasks such as hull cleaning, biofouling assessments, non-destructive testing (NDT), seabed mapping, and marine infrastructure monitoring. The MAVERIC employs a hybrid cleaning method that combines mechanical and hydrodynamic systems, resulting in a lightweight and manoeuvrable design. This allows for deployment from various platforms, including ships and small crafts, reaching areas inaccessible to larger systems. Nosman said: 'We've been on board, at sea, and in the boardrooms. We know how much the industry relies on fragile workarounds. With the MAVERIC, we're introducing a smarter way to work beneath the surface.' The MAVERIC aims to reduce logistical footprints, minimise diver involvement, and enhance turnaround times while maintaining effectiveness. The platform supports both reactive and proactive cleaning strategies, providing vessel operators the flexibility to maintain hull conditions without extensive downtime or expensive dry-docking. Operability is another key feature of the MAVERIC, as it can be operated by a ship's existing crew with minimal training. This promotes wider access to underwater robotics for on-the-spot inspections and maintenance, reducing reliance on specialist contractors and enhancing operational efficiency during routine inspections or light maintenance. Soho said: 'When we think about sustainability in maritime, it's not only about emissions. It's about people, time, and intelligent resource use. 'The MAVERIC is our answer to a future that demands more from fewer people, less from the planet, and everything from technology.' Currently, the technology suite associated with the MAVERIC is undergoing testing, with future modules planned for underwater surveying, hull condition analysis, safety inspections, and security operations. Sea Teknik Robotics aims to streamline ship maintenance processes by consolidating various tools and functions into a cohesive platform. As the company prepares for a commercial launch in the first quarter of 2026, it is actively seeking strategic partners to expedite development, particularly in safety-related applications of the MAVERIC. "Sea Teknik Robotics launches MAVERIC to transform maritime maintenance" was originally created and published by Ship Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
05-06-2025
- Business
- Yahoo
Australia unleashes twin AI supercomputers in push to lead medical, climate research
Australia's AI supercomputing ambitions are hitting top gear, with two major launches unveiled this week that aim to supercharge research in medicine, climate science, and Melbourne, La Trobe University has switched on the country's first AI supercomputer of its kind—a NVIDIA DGX H200 system—dedicated to transforming medical at NEXTDC's data centre in Tullamarine, the supercomputer is backed by $10 million from the Allan Labor for Economic Growth and Jobs Danny Pearson, who visited the site, said: 'Victoria is proud to be home to this supercomputer that will deliver more medical breakthroughs and improve healthcare for Victorians and people around the world.' The system will enable the Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI) to analyse large volumes of health data and complex 3D imaging in hours, drastically reducing research time for projects such as clinical trials, precision oncology, immunotherapy, and cardiovascular risk prediction.'The potential of AI in medical and biotech research is huge,' said La Trobe Vice-Chancellor Professor Theo Farrell.'The DGX H200 enables faster translation of research into clinical trials and personalised therapies.'The supercomputer will also support innovations in digital pathology and cancer relapse-risk prediction, with early projects including a partnership with The Florey Institute on rare neurological diseases such as Niemann-Pick type C.'The super processing performance of NVIDIA DGX H200 systems will help us explore more options and get results faster,' said Dr Ya Hui Hung from The Monash University has announced its own major push into AI computing with MAVERIC—short for Monash AdVanced Environment for Research and Intelligent by a AU$60 million (US$39 million) investment, the system will be built over the next two years, with activation expected in 2026. According to the university, MAVERIC will 'fill a critical gap in Australia's high-performance computing infrastructure,' and position the institution as a 'leader in AI-driven research within the international higher education and research sector.'The platform will initially be used for early cancer detection, managing chronic diseases, empowering clinical trials, and accelerating drug discovery. It will also power climate change and planetary health research, analysing complex datasets related to air quality, Antarctic ecosystems, and the effects of heat on populations.'Investment in world-leading AI is a crucial step in supercharging our sovereign research capabilities,' said Monash Vice-Chancellor Sharon Pickering.'Monash is a well-established ecosystem of world-class researchers, health networks and partners with large-scale data and pre-identified massive research questions ready to be solved… Until now, the missing link has been the necessary compute infrastructure to fully maximise this opportunity,' she university said MAVERIC will be powered entirely by renewable energy, aligning with its net-zero targets. It also plans to use the platform for training students in ethical, human-centred AI development across undergraduate and postgraduate already operates high-performance systems like M3 and MonARCH, comprising thousands of CPU cores and multiple GPU nodes.
